ZIOPHARM Oncology Inc (ZIOP) Rating Increased to Hold at ValuEngine
ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Monday.
Several other research analysts have also weighed in on the company. HC Wainwright started coverage on ZIOPHARM Oncology in a report on Thursday, June 1st. They set a “buy” rating and a $9.50 target price on the stock. BidaskClub lowered ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $13.17.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) traded up 7.36% on Monday, hitting $6.13. The stock had a trading volume of 2,286,495 shares. The company’s 50-day moving average price is $5.70 and its 200 day moving average price is $6.29. ZIOPHARM Oncology has a 12-month low of $4.84 and a 12-month high of $7.88. The firm’s market cap is $862.07 million.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $1.66 million. The business’s revenue was down 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.01) earnings per share. On average, equities research analysts forecast that ZIOPHARM Oncology will post ($0.56) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/28/ziopharm-oncology-inc-ziop-rating-increased-to-hold-at-valuengine.html.
Several hedge funds have recently modified their holdings of the stock. Vident Investment Advisory LLC raised its stake in shares of ZIOPHARM Oncology by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 137,976 shares of the biotechnology company’s stock worth $875,000 after buying an additional 22,996 shares during the period. Old West Investment Management LLC purchased a new stake in shares of ZIOPHARM Oncology during the first quarter worth approximately $205,000. Morgan Stanley raised its stake in shares of ZIOPHARM Oncology by 19.5% in the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock worth $12,610,000 after buying an additional 324,774 shares during the period. Piermont Capital Management Inc. purchased a new stake in shares of ZIOPHARM Oncology during the first quarter worth approximately $639,000. Finally, State Street Corp raised its stake in shares of ZIOPHARM Oncology by 0.6% in the first quarter. State Street Corp now owns 4,039,207 shares of the biotechnology company’s stock worth $25,607,000 after buying an additional 22,864 shares during the period. Institutional investors own 41.94% of the company’s stock.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Stock Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related stocks with our FREE daily email newsletter.